Drugs / BDM-2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03634085 | May → Aug 2018 | — | Hivih | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BDM-2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03634085 ↗ |
| Action | Inhibit | “Akin to other compounds of this class, the INLAIs predominantly inhibit the late stages of HIV-1 replication.” PMID 37310224 ↗ Jun 2023 |
| Modality | Small molecule | “These small molecules act as molecular glues promoting hyper-multimerization of HIV-1 IN protein to severely perturb maturation of viral particles.” PMID 37310224 ↗ Jun 2023 |
| Route | Oral | “single ascending oral doses of BDM-2” NCT03634085 ↗ |